Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Lung Cancer
Interventions
DRUG

temozolomide

150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months

Trial Locations (17)

15905

Conemaugh Memorial Hospital, Johnstown

16602

Bon Secours-Holy Family Health System, Altoona

19047

Saint Mary Regional Center, Langhorne

19111

Fox Chase Cancer Center, Philadelphia

19464

Pottstown Memorial Regional Cancer Center, Pottstown

08822

Hunterdon Regional Cancer Center, Flemington

08701

Kimball Medical Center, Lakewood

08332

South Jersey Regional Cancer Center, Millville

08060

Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly

07701

Riverview Medical Center - Booker Cancer Center, Red Bank

08755

Community Medical Center, Toms River

08629

St. Francis Medical Center, Trenton

19026-1186

Delaware County Memorial Hospital, Drexel Hill

17105-8700

Pinnacle Health Hospitals, Harrisburg

19446-1200

Central Montgomery Medical Center, Lansdale

19301-1792

Paoli Memorial Hospital, Paoli

19612-6052

Reading Hospital and Medical Center, Reading

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT00022711 - Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter